AVATAR-Group


AVATAR - Alliance for Vascular Access Teaching and Research Group, Griffith University, Brisbane, Australia


www.avatargroup.org.au

The Alliance Vascular Access Teaching and Research (AVATAR) group, led by Professor Claire Rickard (Griffith University), have collaborators that include researchers, clinicians, educators and industry from Australia, New Zealand and the United States of America. All AVATAR-ians are committed to scientific work to improve hospital and home care vascular access practices, to rigorously and independently test new products, and to promote global networks of vascular access researchers.

Interested in knowing more about AVATAR? It’s simple. There are no membership fees or forms to apply, just register for our mailing list and you will receive our newsletters. The group has launched its official website – www.AVATARgroup.org.au Here you can find information regarding current research trials, our research team, partner hospitals, teaching and training, and industry collaborations. If a particular study or results are of interest to you, you can contact us for more information. Periodically you will also receive requests to participate in surveys or studies, you can feel free to participate or not, it’s always up to you.

IVNNZ Inc. receive regular updates on developments and progress by the AVATAR group and these will be posted here.


One Million Global catheters: PIVC worldwide prevalence study (OMG study)


You may be aware that the OMG study is shaping up to be the largest clinical benchmarking study ever undertaken with peripheral cannulas. The study aims to compare the current state of peripheral intravascular device use and practices from hospitals across the world. The study is independent of any manufacturer and be rest assured that raw data will not be provided to any commercial entity or employee. However we gratefully acknowledge the support of our industry colleagues in publicising the study among their networks, and in providing funds to support some of our costs in running this large international study.

We have been very busy translating forms, recruiting sites and developing the database that will be multi-lingual. We have approximately 350 hospitals in 30 countries that have expressed interest in this project. Registered sites have also been busy getting ethical approval applications if this is required. A pilot study was undertaken in January and February this year. We surveyed patients across hospitals in 13 countries. We received valuable feedback from the participating sites and have adjusted our data form as required. We are happy to say that we are now ready to proceed with recruitment for the main study. It will provide much needed data on peripheral intravascular device care that can easily be translated into clinical practice. Feedback so far from registered sites is that they see more benefit from getting a group of hospitals in their own region involved so that they can also benchmark locally against each other as well as nationally and internationally. We have adopted a flexible design for this prevalence study to accommodate the logistics of gathering data globally. Each organisation will conduct the study during one day of their choosing later in 2014 or 2015. You can collect data from your entire hospital, or for as many beds as you are able to audit – either way we will be pleased for any help to reach that magic number of one million!

We would like to say thank you again to the many hospitals that participated in the pilot study across thirteen nations. We were very pleased with the number of patients that were screened for the pilot and were able to get a good indication of how we can measure the number with a peripheral intravascular device in place or with no intravascular devices, as well as those with a central venous access device. It was interesting also reviewing the data on clinical signs of phlebitis. The pilot has given us a good indication of how much valuable data we can obtain from this study and the different ways it can be tabulated (e.g. catheter size and phlebitis, bordered versus non bordered dressings, catheter placement site and phlebitis by country etc.). We will be publishing the pilot study results and all collaborating hospitals will be named and acknowledged in the publication (similarly with the main study). We would like to thank our collaborators for helping us with the pilot study.

OMG Study Coordinators: Evan Alexandrou and Gillian Ray-Barruel

Email: omgstudy-group@griffith.edu.au

Website:http://www.omgpivc.org/

 


Intravascular device administration sets: Replacement after Standard vs Prolonged use: The RSVP Trial



AVATAR Newsletter


December 2015

February 2016

May 2016